Goldman Sachs’ top pharmaceutical analyst is leaving the bank.
Jami Rubin said in an email, obtained by Business Insider, that she planned to become a banker and strategic adviser.
A Goldman Sachs spokeswoman confirmed the contents of the email.
Rubin, who’s been an analyst since the early 1990s, has famously pressed major pharmaceutical companies on their plans for mergers and acquisitions. She joined Goldman Sachs in 2008 after working at Morgan Stanley and became a partner in 2012.
At Goldman Sachs, she’s covered companies including Pfizer, Merck, Bristol-Myers Squibb, Johnson & Johnson, and Allergan. For years, she repeatedly asked Pfizer about its plan to break up and spin off some of its businesses, a refrain that has carried over into other massive pharmaceutical companies.
In 2016, Fortune called Rubin the “Conglomerate Killer.”
“I am going to miss playing the ‘activist’ analyst and asking tough questions,” Rubin said in the email.
from Viral Trendy Update https://ift.tt/2qqa5tC
via IFTTT
0 Comments